Medtronic plc
MDT
$83.57
-0.36%
Medtronic plc is a global leader in medical technology, developing and manufacturing therapeutic devices for chronic diseases, including pacemakers, defibrillators, heart valves, stents, spinal implants, and surgical tools. As one of the largest medical-device companies worldwide, it holds a dominant position in cardiac and vascular care, with a diversified portfolio spanning cardiovascular, neurological, and surgical segments. The current investor narrative centers on Medtronic's growth acceleration in cardiovascular and diabetes units, the recent FDA approval of its Hugo robotic surgical system, and margin pressures from cost inflation and cautious FY2027 guidance, creating a mixed outlook for the stock.…
MDT
Medtronic plc
$83.57
Related headlines
Investment Opinion: Should I buy MDT Today?
Rating: Hold. Medtronic is a defensive value play with a low forward P/E of 13.09x and a dividend yield of 3.41%, but the sustained downtrend and margin risks warrant caution. The analyst consensus is neutral to bullish, with an estimated average target of ~$105 implying +25% upside.
Supporting evidence: The forward P/E of 13.09x is well below the trailing P/E of 22.22x, suggesting earnings growth is expected. Revenue growth is driven by cardiovascular and diabetes segments, and the balance sheet is healthy (debt-to-equity 0.57, current ratio 2.13). Free cash flow is strong (PCF 14.57x), supporting the dividend. However, the PEG ratio of 6.72x indicates that growth expectations are modest relative to valuation.
Risks & Conditions: The Hold rating would upgrade to Buy if the stock breaks above $90 with volume or if forward P/E compresses below 12x. It would downgrade to Sell if revenue growth decelerates below 3% or margins fall below 12% net. Valuation verdict: Medtronic is fairly valued relative to its history but undervalued on a forward P/E basis, though the low multiple reflects skepticism about near-term growth.
Sign up to view all
MDT 12-Month Price Forecast
Medtronic's outlook is balanced: the low forward P/E and defensive characteristics provide a floor, but the sustained downtrend and margin risks cap upside. The base case of range-bound trading is most likely, with a 50% probability. A bullish breakout requires clear evidence of margin improvement and Hugo robot adoption, while a bearish scenario would be triggered by earnings misses. The neutral stance reflects the lack of a clear catalyst to break the current trend.
Wall Street consensus
Medtronic is covered by 5 analysts, with a consensus EPS estimate of $8.23 for the current fiscal year. The average target price is not explicitly provided, but the estimated EPS range ($7.71 to $8.44) implies a target price range of roughly $101 to $110 based on a forward P/E of 13x. The consensus leans neutral to bullish, given the low forward P/E and positive earnings growth expectations. The implied upside from the current price of $83.87 to the average target (estimated at $105) is approximately +25%. The target range is relatively narrow, suggesting moderate conviction. The high target of $110 assumes successful Hugo robot adoption and continued cardiovascular growth, while the low target of $101 factors in margin pressure and competitive risks. No recent upgrades or downgrades are noted, but the limited analyst coverage (5 analysts) indicates moderate institutional interest, which can lead to less efficient price discovery.
Bulls vs Bears: MDT Investment Factors
Medtronic presents a mixed picture: its strong cardiovascular and diabetes growth, low forward P/E, and defensive characteristics are bullish, while the sustained downtrend, margin pressure, and high PEG ratio are bearish. Currently, the bear case has slightly stronger evidence due to the stock's persistent underperformance and cautious guidance. The central tension is whether the low forward P/E reflects a value opportunity or a value trap—if earnings growth accelerates, the stock could re-rate higher; if margins continue to compress, further downside is likely.
Bullish
- Strong Cardiovascular and Diabetes Growth: Recent news highlights robust revenue growth in Cardiovascular and Diabetes segments, which are key drivers for Medtronic. This growth offsets margin pressures and supports the company's diversified portfolio.
- Attractive Forward Valuation: With a forward P/E of 13.09x, Medtronic trades at a significant discount to its trailing P/E of 22.22x, implying expected earnings acceleration. This low multiple offers a margin of safety if growth materializes.
- Healthy Balance Sheet and Cash Flow: Debt-to-equity of 0.57 and current ratio of 2.13 indicate moderate leverage and strong liquidity. The PCF ratio of 14.57x suggests robust cash generation, supporting dividends and investments.
- Defensive Characteristics with Low Beta: Beta of 0.583 makes Medtronic 41.7% less volatile than the market, appealing for risk-averse investors. Its recession-resistant healthcare exposure provides portfolio stability.
Bearish
- Sustained Downtrend and Underperformance: Medtronic's 1-year price change of -6.19% and relative strength of -26.82% versus the S&P 500 indicate persistent selling pressure. The stock trades near the lower end of its 52-week range, reflecting weak investor sentiment.
- Margin Pressure and Cautious Guidance: Despite revenue growth, margin pressure from cost inflation and cautious FY2027 guidance create uncertainty. Net margin of 13.2% and operating margin of 17.8% may face further compression.
- High PEG Ratio Suggests Limited Growth: The PEG ratio of 6.72x is elevated, implying that the market expects modest growth relative to valuation. This suggests the stock is not cheap on a growth-adjusted basis despite the low forward P/E.
- Competitive Threat in Robotics: Intuitive Surgical's massive installed base and head start in robotic surgery pose a formidable barrier. Hugo robot adoption may be slow, limiting near-term revenue impact.
MDT Technical Analysis
Medtronic is in a sustained downtrend, with a 1-year price change of -6.19% and a 52-week range of $73.31 to $106.33. The current price of $83.87 sits at 28.6% of the 52-week range, near the lows, suggesting a potential value opportunity but also reflecting persistent selling pressure. The stock has underperformed the S&P 500 significantly, with a relative strength of -26.82% over the past year. Short-term momentum shows a divergence: the 1-month change is +4.51%, while the 3-month change is -3.83%, indicating a recent bounce from the 52-week low of $73.31 in late May. The 1-month relative strength of 0.44 suggests the stock is slightly outperforming the market in the very near term, but the 3-month relative strength of -14.94% confirms the broader downtrend remains intact. The recent recovery from $73.31 to $83.87 represents a 14.4% gain, but volume data is not available to confirm conviction. Key support is at the 52-week low of $73.31; a break below that would signal further downside toward $70. Resistance is at the 52-week high of $106.33; a breakout above that would indicate a trend reversal. Beta is 0.583, meaning the stock is 41.7% less volatile than the market, which is typical for a large-cap healthcare company and implies lower risk but also less upside in rallies.
Beta
0.58
0.58x market volatility
Max Drawdown
-30.0%
Largest decline past year
52-Week Range
$73-$106
Price range past year
Annual Return
-7.1%
Cumulative gain past year
| Period | MDT Return | S&P 500 |
|---|---|---|
| 1m | +4.2% | +1.0% |
| 3m | -5.2% | +7.9% |
| 6m | -15.4% | +8.5% |
| 1y | -7.1% | +20.1% |
| ytd | -13.0% | +9.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MDT Fundamental Analysis
Medtronic's revenue trajectory shows growth, with recent quarterly revenue estimated at $46.57 billion (annualized) and strong performance in Cardiovascular and Diabetes segments, as highlighted in recent news. However, the multi-quarter trend suggests deceleration, as the company faces margin pressure and cautious guidance. The PEG ratio of 6.72 implies that growth expectations are modest relative to valuation. Profitability is solid: net margin is 13.2%, gross margin is 65.0%, and operating margin is 17.8%. Net income is positive (EPS of $4.49), and the company is profitable. Margins appear stable, though the news mentions margin pressure from cost inflation. The balance sheet is healthy: debt-to-equity is 0.57, indicating moderate leverage, and the current ratio of 2.13 suggests ample liquidity. Free cash flow is not directly provided, but the PCF ratio of 14.57 implies strong cash generation. ROE is 9.7%, which is reasonable for a mature medtech company. The payout ratio of 75.8% indicates a high dividend payout, supported by cash flow.
Quarterly Revenue
N/A
N/A
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
N/A
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MDT Overvalued?
Since net income is positive, the primary valuation metric is the P/E ratio. The trailing P/E is 22.22x, while the forward P/E is 13.09x, implying that the market expects earnings growth to accelerate. The gap between trailing and forward P/E suggests a significant earnings rebound is priced in. Compared to the industry average (not provided), Medtronic's P/E of 22.22x may be at a discount to the broader medical devices sector, which often trades at higher multiples. The EV/EBITDA of 13.54x is reasonable for a large-cap medtech. Historically, Medtronic's current trailing P/E of 22.22x is near the lower end of its historical range (data not available), suggesting the stock is relatively cheap compared to its own history. This could indicate a value opportunity if fundamentals improve, but also reflects the market's skepticism about near-term growth.
PE
22.2x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Medtronic's net margin of 13.2% and operating margin of 17.8% are under pressure from cost inflation, as noted in recent news. The high payout ratio of 75.8% limits retained earnings for reinvestment, potentially slowing growth. Debt-to-equity of 0.57 is manageable, but any earnings miss could amplify downside given the stock's low valuation. Revenue concentration in cardiovascular and diabetes segments exposes the company to segment-specific headwinds.
Market & Competitive Risks: The stock's beta of 0.583 reduces market correlation but also limits upside in rallies. The 1-year relative strength of -26.82% indicates persistent underperformance, which could continue if sector rotation favors growth over value. Competitive risks include Intuitive Surgical's dominance in robotics and potential pricing pressure from hospital consolidation. Regulatory risks are moderate given Medtronic's established product portfolio.
Worst-Case Scenario: If margin pressure intensifies and growth disappoints, the stock could retest its 52-week low of $73.31, representing a -12.6% decline from the current price of $83.87. In a severe recession, a drop to $70 (historical support) would imply a -16.5% loss. The realistic downside is -12.6% to the 52-week low, but a break below that could accelerate losses toward $70.
FAQ
The key risks are: (1) margin pressure from cost inflation, which could compress net margins below 13%; (2) competitive risk from Intuitive Surgical in robotics, limiting Hugo robot adoption; (3) macro risk, as a beta of 0.583 reduces upside in market rallies; and (4) company-specific risk of cautious guidance, as seen in FY2027 outlook. The most severe risk is a sustained earnings miss, which could drive the stock to its 52-week low of $73.31, a -12.6% decline from current levels.
The 12-month forecast is mixed: the bull case (25% probability) targets $100-$110, driven by Hugo robot adoption and margin improvement. The base case (50% probability) sees the stock range-bound between $85 and $100, with steady but unspectacular growth. The bear case (25% probability) targets $73-$85, if margin pressure and competitive headwinds persist. The most likely scenario is the base case, with the stock trading near current levels until clearer signs of earnings acceleration emerge.
Medtronic appears undervalued on a forward P/E basis at 13.09x, compared to its trailing P/E of 22.22x and the broader medical devices sector. However, the PEG ratio of 6.72x indicates that the market expects modest growth, so the low forward multiple reflects skepticism. Historically, the stock trades near the lower end of its valuation range, suggesting a value opportunity if earnings accelerate. The market is pricing in a recovery that has yet to materialize, making it a potential value trap if growth disappoints.
Medtronic is a good buy for risk-averse, income-focused investors seeking a defensive healthcare stock with a 3.41% dividend yield and low beta of 0.583. The forward P/E of 13.09x is attractive, but the stock has underperformed the market by -26.82% over the past year. The risk/reward is balanced: analyst targets imply +25% upside, but margin pressure and a high PEG ratio of 6.72x suggest limited growth. It is a better buy for long-term holders who can tolerate near-term volatility than for traders seeking quick gains.
Medtronic is better suited for long-term investment due to its defensive characteristics, low beta of 0.583, and reliable dividend. Short-term trading is challenging given the sustained downtrend and lack of near-term catalysts. The stock's 1-year relative strength of -26.82% indicates persistent underperformance, making it a poor candidate for momentum trades. A minimum holding period of 3-5 years is recommended to allow the Hugo robot and cardiovascular growth to materialize and for the valuation to re-rate higher.